ATE302613T1 - Proteinfarnesyltransferase-inhibitoren in kombination mit hmgcoa-reduktase-inhibitoren zur behandlung von aids - Google Patents

Proteinfarnesyltransferase-inhibitoren in kombination mit hmgcoa-reduktase-inhibitoren zur behandlung von aids

Info

Publication number
ATE302613T1
ATE302613T1 AT96926596T AT96926596T ATE302613T1 AT E302613 T1 ATE302613 T1 AT E302613T1 AT 96926596 T AT96926596 T AT 96926596T AT 96926596 T AT96926596 T AT 96926596T AT E302613 T1 ATE302613 T1 AT E302613T1
Authority
AT
Austria
Prior art keywords
inhibitors
aids
treatment
combination
farnesyl transferase
Prior art date
Application number
AT96926596T
Other languages
English (en)
Inventor
Mari Yonemoto
Kenji Tanaka
Yoshikazu Iwasawa
Original Assignee
Banyu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Pharma Co Ltd filed Critical Banyu Pharma Co Ltd
Application granted granted Critical
Publication of ATE302613T1 publication Critical patent/ATE302613T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
AT96926596T 1995-08-09 1996-08-08 Proteinfarnesyltransferase-inhibitoren in kombination mit hmgcoa-reduktase-inhibitoren zur behandlung von aids ATE302613T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP22465995 1995-08-09
PCT/JP1996/002241 WO1997005902A1 (fr) 1995-08-09 1996-08-08 Composition medicinale

Publications (1)

Publication Number Publication Date
ATE302613T1 true ATE302613T1 (de) 2005-09-15

Family

ID=16817199

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96926596T ATE302613T1 (de) 1995-08-09 1996-08-08 Proteinfarnesyltransferase-inhibitoren in kombination mit hmgcoa-reduktase-inhibitoren zur behandlung von aids

Country Status (5)

Country Link
US (1) US6083985A (de)
EP (1) EP0856315B1 (de)
AT (1) ATE302613T1 (de)
DE (1) DE69635114T2 (de)
WO (1) WO1997005902A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6524832B1 (en) 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
GB9801231D0 (en) 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
UA57081C2 (uk) * 1997-06-16 2003-06-16 Пфайзер Продактс Інк. Фармацевтична композиція для лікування раку або доброякісних проліферативних хвороб у ссавців, спосіб лікування, фармацевтична композиція для інгібування ненормального росту клітин у ссавців та спосіб інгібування
US20030114503A1 (en) * 1997-06-16 2003-06-19 Pfizer Inc. Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the treatment of cancer
US6096757A (en) 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
TW581763B (en) * 1997-12-22 2004-04-01 Schering Corp Combination and pharmaceutical composition comprising FPT inhibitor for treating proliferative diseases
US6576436B1 (en) * 1998-12-09 2003-06-10 The Arizona Disease Control Research Commission Anticancer agents based on prevention of protein prenylation
US6191147B1 (en) * 1998-12-24 2001-02-20 Ppd Discovery, Inc. Pyrazole compounds and uses thereof
JP2002536405A (ja) * 1999-02-11 2002-10-29 イーデンランド、インコーポレイテッド ウイルス感染症の治療方法
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
CA2632091C (en) 2000-12-19 2011-03-22 Pfizer Products Inc. Crystal forms of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1h-quinolin-2-one, 2,3-dihydroxybutanedioate salts and method of production
US20020151563A1 (en) * 2001-03-29 2002-10-17 Pfizer Inc. Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
US6602907B1 (en) * 2001-06-08 2003-08-05 University Of Central Florida Treatment of breast cancer
US6740757B2 (en) 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
TW200806284A (en) * 2006-03-31 2008-02-01 Alcon Mfg Ltd Prenyltransferase inhibitors for ocular hypertension control and the treatment of glaucoma
WO2010075887A1 (en) * 2008-12-30 2010-07-08 Oxyrane (Uk) Limited Methods and intermediates useful in the synthesis of hexahydrofuro[2,3-b]furan-3-ol
US10369220B2 (en) * 2016-10-04 2019-08-06 Cellprint Ip Holding, Llc Methods and compositions for affecting immunological responsiveness

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2044333A1 (en) * 1990-06-12 1991-12-13 Jackson B. Gibbs Chemotherapeutic agents
EP0537008B1 (de) * 1991-10-11 1995-10-25 E.R. SQUIBB & SONS, INC. Verwendung von Biphosphonaten zur Herstellung eines Arzneimittels zur Blockierung neoplastischer Zelltransformationen die durch Ras-Oncogene verursacht werden
US5286895A (en) * 1992-02-19 1994-02-15 Merck & Co., Inc. Cholesterol lowering compounds
JPH07316076A (ja) * 1994-05-24 1995-12-05 Sankyo Co Ltd 制癌剤
EP0776884B1 (de) * 1994-08-11 2000-01-05 Banyu Pharmaceutical Co., Ltd. Substituierte amidderivate
EP0836383A1 (de) * 1995-06-29 1998-04-22 Merck & Co., Inc. Kombinationen von inhibitoren von farnesyl protein transferase

Also Published As

Publication number Publication date
US6083985A (en) 2000-07-04
EP0856315A1 (de) 1998-08-05
DE69635114T2 (de) 2006-03-02
DE69635114D1 (de) 2005-09-29
EP0856315A4 (de) 2003-04-23
EP0856315B1 (de) 2005-08-24
WO1997005902A1 (fr) 1997-02-20

Similar Documents

Publication Publication Date Title
ATE302613T1 (de) Proteinfarnesyltransferase-inhibitoren in kombination mit hmgcoa-reduktase-inhibitoren zur behandlung von aids
HUP9900962A2 (hu) Fertőtlenítőkészítmények és eljárások felületek fertőtlenítésére
ATE302015T1 (de) Zusammensetzung, welche apoptosis verhindert, methode zur reinigung dieser zusammensetzung und verwendungen davon
TR199903331T2 (xx) Farnesil protein transferas engelleyicileri.
TR199701056T1 (xx) Farnesil-protein transferaz enzimi inhibit�rleri.
DE69910368D1 (de) Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
ID29393A (id) Komposisi pengobatan kanker dan metoda penggunaan minyak-minyak esensil tanaman alamiah
ATE311853T1 (de) Verwendung von krillenzymen zur behandlung von zahnbelag
DE69728594D1 (de) Chromfreie Zusammensetzung zur Behandlung von Metalloberflächen
DE50010115D1 (de) Zusammensetzung und verfahren zur entkeimung von luft
DE60114171D1 (de) Minoxidil enthaltende zubereitung
DE60013098D1 (de) Zusammensetzung zur hautdesinfizierung
ES2193919T3 (es) Inhibidores de la enzima convertidora de endotelina.
DE69814444D1 (de) Kombination von angiotensing-convertin-enzyme hemmern mit diuretikum zur behandlung von störungen der mikrozirkulation
ATE283044T1 (de) Compactin zur behandlung von entzündungen
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
DE60032002D1 (de) Verfahren zur herstellung von antimikrobiellen parfümierenden zusammensetzungen
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
ES2164911T3 (es) Composicion farmaceutica que contiene inhibidores de interferon gamma.
DE69429013D1 (de) Verwendung von dimeticon zur behandlung der konstipation
ATE231721T1 (de) Verwendung von tropolon derivate zur hemmung des inositmono phosphatase
DE69930419D1 (de) Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
ATE209005T1 (de) Verwendung von threonin zur behandlung der phenylketonurie
ATE241382T1 (de) Verwendung von lactoferrin zur prävention des nachoperativen astigmatismus

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties